CFTR and cystic fibrosis: In CF, a pharmaceutical company, Vertex, has successfully used human primary cells isolated from the bronchi of a patient with G551D and F508del CFTR mutations to determine the efficiency of Ivacaftor and Lumacaftor drugs [158].